SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent Power Solutions is attracting attention following a strong earnings report that highlighted significant year-over-year revenue growth and a substantial expansion in its order backlog. While some traders express frustration regarding the company's recent share offerings and insider activity, many are focused on the long-term potential of the firm's role in the power infrastructure buildout for AI data centers.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The index is trending amid volatility driven by conflicting signals regarding AI development, rising Treasury yields, and uncertainty ahead of the Federal Reserve's upcoming rate decision. Traders are reacting to aggressive intraday price swings, with significant disagreement between those anticipating further declines due to inflationary pressures and those betting on a continued recovery.

Vera Therapeutics, Inc. is a clinical stage biotechnical company, which engages in the development and commercialization of transformative treatments for immunological diseases. Its product includes the TRUTAKNA injection. The company was founded by Marshall W. Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is currently the focus of market attention as investors anticipate upcoming Phase 3 ORIGIN 3 clinical data for its IgA nephropathy treatment, with many pointing to a high short interest and potential buyout interest as catalysts for a significant move. The community remains largely bullish, emphasizing the asset's clinical promise and institutional backing while awaiting the data release by the end of the third quarter.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is currently under downward pressure due to a combination of persistent insider selling and broad sector volatility linked to AI and data center infrastructure concerns. While some traders are highlighting the stock's significant long-term growth potential and large-scale data center contracts as a basis for a bullish outlook, others express frustration over recent price underperformance and market sentiment regarding AI development.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is receiving significant attention as the community debates the company's long-term growth prospects, centered on the upcoming Iridium acquisition and the development of the Neutron rocket. While many traders remain bullish on these catalysts and recent positive news regarding solar cell technology, others express skepticism, citing concerns over potential share dilution, delayed launch timelines, and broader market volatility.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics is trending as traders speculate on positive guidance updates following the company's recent healthcare conference participation and anticipation of upcoming Phase 2 NSCLC trial data. While the stock has seen significant momentum, community sentiment remains focused on institutional accumulation and the expectation that the company's solid tumor platform and clinical milestones will drive long-term value.

Oracle Corporation. The Group's principal activities are to develop, manufacture, market, distribute and service computer software. It has two businesses, software and services, which are further divided into five segments. Its software business consist of two segments: The new software license segment is engaged in the licensing of database, middleware software and applications software.The software license updates and product support segment provides customers with rights to unspecified software product upgrades and maintenance releases, internet access to technical content, internet and telephone access to technical support personnel. Its services business is comprised of three segments: The consulting segment provides services in business strategy and analysis, business process simplification, solutions integration and the implementation, enhancement and upgrade of database, middleware and applications software. On Demand includes Oracle On Demand and Advanced Customer Services.

Oracle Corp.

Oracle is trending following reports of a fresh round of job cuts alongside sustained multi-billion dollar capital expenditures for AI infrastructure. Traders are debating whether these workforce reductions signal improved operational efficiency and long-term bullishness or indicate an underlying slowdown in AI-related momentum.

Polestar Automotive Holding UK Plc is the Swedish electric performance car brand that engages in the research, development, marketing, commercialization, and sales of battery electric vehicles and related technology solutions. It offers Polestar 2 (PS2), a premium fast-back sedan, the Polestar 3 (PS3), a luxury aero sport-utility vehicle, the Polestar 4 (PS4), a premium sport utility vehicle, the Polestar 5 (PS5), a luxury sport grand-touring sedan, and the Polestar 6 (PS6), a luxury roadster. The company was founded on September 15, 2021 and is headquartered in Gothenburg, Sweden.

Polestar Automotive Holding UK PLC - ADR Class A

Polestar Automotive Holding UK PLC

Polestar shares have faced significant pressure following a government decision to ban new vehicle sales in the U.S. starting in 2027 due to connected-vehicle data security concerns. The community is divided between skepticism regarding the company's long-term financial viability and bankruptcy risk, and optimism about a strategic pivot to focus growth efforts on the European and Canadian markets.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

Quantum Computing Inc. is trending as traders speculate on a potential short squeeze, citing significant short interest and upcoming earnings, while others highlight institutional accumulation and long-term potential in the quantum hardware space. Discussion is heavily focused on the company's $1.3 billion cash position relative to its valuation, with some community members debating its competitive advantage in room-temperature photonic computing.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as traders focus on the Federal Reserve's upcoming policy meeting, with a significant majority anticipating a rate hike amid persistent inflation concerns. The community remains divided between those expecting potential volatility from higher bond yields and those speculating that the central bank may keep rates unchanged.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion

Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion...

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Canaccord Genuity Group Raises Sagimet Biosciences (NASDAQ:SGMT) Price Target to $49.00

Canaccord Genuity Group raised their target price on Sagimet Biosciences from $28.00 to $49.00 and gave the stock a 'buy' rating in a research note on Monday...

Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise

Sagimet Biosciences (NASDAQ:SGMT) said it is sharpening its strategic focus on developing differentiated therapies for patients with moderate to severe acne, with plans to advance its lead fatty acid...

Guggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00

Guggenheim cut their target price on Sagimet Biosciences from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday...

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with technicals showing strong momentum.read more...

Why Sagimet Biosciences Stock Is Soaring Today

Key PointsSagimet Biosciences is developing a handful of drugs, but its priority is acne therapies...

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Sagimet Biosciences Inc - Ordinary Shares - Series A

SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months – What’s Got Retail Buzzing?

Equity

Bearish Sentiment

50bps hike

25bps hike

No change

25bps cut

The Federal Reserve's September FOMC meeting concludes Wednesday, September 16, with a rate decision due at 2:00 PM ET, following Tuesday's CPI report that showed inflation still running above the Fed's 2% target. What do you think the Fed decides at this week's FOMC meeting? Vote and explain your reasoning in the comments.

The Fed&#39;s rate decision comes Wednesday at 2PM ET. What do you think happens?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.26	--	--	N/A
Q2 '26	-$0.25	-$0.26	-3.59%	MISSED
Q1 '26	-$0.37	-$0.33	11.03%	BEAT
Q4 '25	-$0.43	-$0.29	32.90%	BEAT
Q3 '25	-$0.39	-$0.40	-3.63%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

SGMT Earnings

Upcoming Earnings: Q3 '26

Historical Earnings